Archive for the ‘research’ Category

COVID-19 Vaccine Associated Parkinson’s Disease

https://scivisionpub.com/pdfs/covid19-vaccine-associated-parkinsons-disease-a-prion-disease-signal-in-the-uk-yellow-card-adverse-event-database-1746.pdf

COVID-19 Vaccine Associated Parkinson’s Disease, A Prion Disease Signal in the UK Yellow Card Adverse Event Database

Citation: Classen JB. COVID-19 Vaccine Associated Parkinson’s Disease, A Prion Disease Signal in the UK Yellow Card Adverse Event Database. J Med – Clin Res & Rev. 2021; 5(7): 1-6.

* Correspondence: J. Bart Classen, MD, Classen Immunotherapies, Inc, 3637 Rockdale Road, Manchester, MD 21102, Tel: 410-377-8526. Received: 25 June 2021; Accepted: 18 July 2021

ABSTRACT

Many have argued that SARS-CoV-2 spike protein and its mRNA sequence, found in all COVID-19 vaccines, are priongenic. The UK’s Yellow Card database of COVID-19 vaccine adverse event reports was evaluated for signals consistent with a pending epidemic of COVID vaccine induced prion disease. Adverse event reaction rates from AstraZeneca’s vaccine were compared to adverse event rates for Pfizer’s COVID vaccines. The vaccines employ different technologies allowing for potential differences in adverse event rates but allowing each to serve as a control group for the other. The analysis showed a highly statistically significant and clinically relevant (2.6-fold) increase in Parkinson’s disease, a prion disease, in the AstraZeneca adverse reaction reports compared to the Pfizer vaccine adverse reaction reports (p= 0.000024). These results are consistent with monkey toxicity studies showing infection with SARS-CoV-2 results in Lewy Body formation.

The findings suggest that regulatory approval, even under an emergency use authorization, for COVID vaccines was premature and that widespread use should be halted until full long term safety studies evaluating prion toxicity has been complete. Alternative vaccines like the Measles Mumps Rubella (MMR) vaccine should be explored for those desiring immunization against COVID-19.

___________________

**Comment**

This is paper #2 from Classen, an immunologist and former NIH contract scientist, showing COVID injections to be extremely dangerous as they can cause prion disease. In his current paper he utilizes 6-months of UK adverse event data on AstraZeneca (uses GM adenoviruses) and Pfizer injections (uses lipid-encapsulated synthetic mRNA), whose goal is to stimulate the spike protein and antibodies, which show clear signs of causing symptoms of neurodegenerative disorders such as Parkinson’s, Alzheimer’s ALS, and others.  

The study showed nervous disorders, tremors, and sleep disturbances, after the COVID injections – all of which are symptoms of prion disease.  

Classen is concerned because the reporting system is set up to report acute events, not neurodegenerative issues, which can be non-specific or overlap with other conditions, which could occur years or decades later.  Due to this, findings could be exponentially higher.

Paper #1 which analyzed the Pfizer injection is here and points out many important details to consider, including an important excerpt from the summary:

Many have raised the warning that the current epidemic of COVID-19 is actually the result of an bioweapons attack released in part by individuals in the United States government [10,11]. Such a theory is not far fetched given that the 2001 anthrax attack in the US originated at Fort Detrick, a US army bioweapon facility. Because the FBI’s anthrax investigation was closed against the advice of the lead FBI agent in the case, there are likely conspirators still working in the US government. In such a scenario the primary focus of stopping a bioweapons attack must be to apprehend the conspirators or the attacks will never cease. Approving a vaccine, utilizing novel RNA technology without extensive testing is extremely dangerous. The vaccine could be a bioweapon and even more dangerous than the original infection.

Important excerpt:

This analysis should serve as an urgent warning to those mindlessly following advice of politicians and public health officials regarding COVID immunization. Both groups have had a dismal record of protecting the health of the public. US public health officials ran the infamous Tuskegee syphilis study allowing people of color to die from syphilis because the public health officials refused to inform the patients, they had syphilis and that a treatment existed. There have been numerous less well-known experiments on prisoners and other vulnerable populations in North America. The infamous Nazi physician Josef Mengele was a public health doctor.…

5 doctors state the injections are bioweapons & what you can do about it. The injections are NOT “vaccines” but cause YOU to manufacture spike proteins – perhaps indefinitely – the very thing causing illness. Those getting the injections are possibly transmitting this spike protein to those foregoing the injections.  

 

Dr. Stephanie Seneff – Risk of Prion Disease video

(Approx. 3 Min)

Category:

Alzheimer's, research, vaccines, Viruses

Lyme Disease Protein Tricks Immune System, Ignites Arthritis

https://danielcameronmd.com/lyme-disease-protein-ignites-arthritis/

LYME DISEASE PROTEIN TRICKS IMMUNE SYSTEM, IGNITES ARTHRITIS

man with lyme disease and arthritis rubbing his knee
Researchers from Virginia Tech believe they have discovered another piece of the Lyme disease puzzle – How does the Borrelia burgdorferi bacterium cause inflammation and Lyme arthritis?
By 

Lyme disease patients often struggle with ongoing symptoms including arthritis. Findings from this latest study are a “testament to how unique this bacterium is — and how we need to keep working to understand more about what is going on behind the scenes in order to develop future diagnostics and treatments,” states Mari Davis, lead author on the paper.

In earlier studies, Brandon Jutras, a Virginia Tech biochemist, discovered that as the “Lyme-causing bacteria Borrelia burgdorferi multiplies, it sheds a cellular component called peptidoglycan that elicits a unique inflammatory response in the body.”¹

Peptidoglycan, he reported, contributes to inflammation and Lyme arthritis.

Peptidoglycan  is an essential component of bacterial cell walls. It was still present in Lyme disease patients weeks to months after the initial infection, inciting inflammation and arthritis, Jutras reported.

NapA protein tricks immune system

But most recently, scientists at the Jutras lab (lead by Brandon Jutras) identified a type of peptidoglycan-associated protein, called Neutrophil Attracting Protein A (NapA) in Borrelia burgdorferi bacterium.

“Using microfluidics, we demonstrate that NapA acts as a molecular beacon—exacerbating the pathogenic properties of B. burgdorferi [peptidoglycan].”²

NapA is an “immunomodulatory molecule that is able to recruit immune cells, called neutrophils, toward the inflammatory peptidoglycan,” the author explains.

“NapA is another piece to an ever-evolving puzzle; it seems to play a basic role in everyday bacterial life by helping the overall protective properties of peptidoglycan,” explains Jutras, “but it moonlights as a devious protein capable of tricking our immune system.”

NapA has two devious sides

“Early in infection, when bacteria are dying and releasing NapA and peptidoglycan, it acts as a decoy to attract immune cells, which allows the viable bacteria to escape and cause disease,” Jutras explains.

“In later stages of disease, it may act to attract immune cells to peptidoglycan, a molecule capable of causing inflammation and arthritis.”

Authors’ Conclusion

The combination of peptidoglycan and NapA could serve as a novel target for prevention and diagnostics developments.

“One thing that we know for sure is that this finding furthers our understanding of how peptidoglycan can drive Lyme arthritis patient symptomology.”

References:
  1. Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis
    Brandon L. Jutras, Robert B. Lochhead, Zachary A. Kloos, Jacob Biboy, Klemen Strle, Carmen J. Booth, Sander K. Govers, Joe Gray, Peter Schumann, Waldemar Vollmer, Linda K. Bockenstedt, Allen C. Steere, Christine Jacobs-Wagner Proceedings of the National Academy of Sciences Jul 2019, 116 (27) 13498-13507; DOI: 10.1073/pnas.1904170116
  2. Marisela M. Davis, Aaron M. Brock, Tanner G. DeHart, Brittany P. Boribong, Katherine Lee, Mecaila E. McClune, Yunjie Chang, Nicholas Cramer, Jun Liu, Caroline N. Jones, Brandon L. Jutras. The peptidoglycan-associated protein NapA plays an important role in the envelope integrity and in the pathogenesis of the lyme disease spirochete. PLOS Pathogens, 2021; 17 (5): e1009546 DOI: 10.1371/journal.ppat.1009546

______________________

For more:

Category:

Lyme, research

Harvard Student, Queen’s Prof, Collaborating to Rapidly Identify Lyme-Infected Ticks

https://www.coastreporter.net/national-news/harvard-student-queens-prof-collaborating-to-rapidly-identify-lyme-infected-ticks-

Harvard student, Queen’s prof, collaborating to rapidly identify Lyme-infected ticks

OTTAWA — Harvard University microbiology student Indumathi Prakash was just seven years old when a tick bite near her home in Massachusetts gave her Lyme disease and left her to spend most of her childhood battling rheumatoid arthritis.
2021071616070-60f1e62aa5ca5b9124ece6c1jpeg

OTTAWA — Harvard University microbiology student Indumathi Prakash was just seven years old when a tick bite near her home in Massachusetts gave her Lyme disease and left her to spend most of her childhood battling rheumatoid arthritis.

Now Prakash, 21, is working with a Queen’s University professor, although virtually, on a rapid test that will diagnose the bacterium that causes Lyme disease in ticks in just a few hours.

If successful, the test will open the door to better and faster treatment for the rapidly expanding disease.

“I really wanted to do something to prevent the same thing from happening to someone else so that’s kind of why I got interested in tick-borne disease in general,” said Prakash, in a phone interview from Cambridge, Mass.

Lyme disease has been around in Canada since the 1980s. Warmer winters over the last decade have allowed ticks, and the pathogens they often carry, to flourish in ways they never did before. (See link for article)

_________________

**Comment**

Interesting that this author doesn’t utilize her own countryman’s independent research showing ticks are impervious to the climate and hide under leaf litter, snow, mulch, etc. when conditions are harsh – but doing so would be defying the accepted narrative that “climate change” is behind tick and disease proliferation, and all the woes on planet earth today, despite climatologists who state otherwise, and we certainly can’t have that.

Important quote: 

Since Lyme disease can often be prevented if antibiotics are started within 24 hours of the bite, doctors routinely give people with tick bites antibiotics before it’s clear the bacteria is present.

No, I’m afraid doctors don’t routinely give people with tick bites antibiotics.  I wish they did – and they certainly should.  Doctors continue to take a “wait and see” approach, which is dooming patients to sometimes a life-time of suffering. In my opinion, it appears doctors would rather diagnose patients with anything but Lyme/MSIDS.

The article points out that ticks can be tested by results often take days to obtain results.  This is another problem with testing – not only for ticks but for humans.

Evidently the new test will also detect other coinfections that often come with Lyme disease.

Category:

Lyme, research, Ticks

Lyme Disease Skin Rash Puzzles Doctors, Leads to Misdiagnoses

https://danielcameronmd.com/lyme-disease-skin-rash-misdiagnoses/

LYME DISEASE SKIN RASH PUZZLES DOCTORS, LEADS TO MISDIAGNOSES

Patient with Lyme disease skin rash

Lyme disease can cause an atypical skin rash that may be mistakenly attributed to another illness, as this case report demonstrates. In their article, Suzuki and colleagues describe a 43-year-old woman who developed a rash which puzzled doctors and led to several misdiagnoses before Lyme disease was correctly identified.

By 
 

Lyme disease can cause an atypical skin rash, which may be overlooked by clinicians. In this case report, a 43-year-old woman, who was an avid gardener and lived in Wisconsin, developed pink papules behind her right knee.1  Over the next several days, the rash “evolved into painless vesicles with surrounding faint erythema.” She also developed fever, chills, neck pain and malaise.

Diagnoses: shingles, cellulitis, necrotizing fasciitis

Doctors initially suspected shingles (Herpes Zoster) but treatment with valacyclovir, an antiviral medication, did not improve the skin rash or symptoms. “The blisters increased in size and showed purple discoloration,” the authors wrote.

The doctors then diagnosed her with cellulitis, a bacterial skin infection which also causes a skin rash. She was prescribed ceftriaxone, followed by cephalexin and trimethoprim-sulfamethoxazole. But the woman remained ill.

She was then referred for evaluation for suspected necrotizing fasciitis, an inflammation of the vessel walls.  At this time, she had a fever of 101.3°F.

“The atypical appearance of skin rash might confuse physicians with many differential diagnoses, such as spider bite, herpes zoster, bullous cellulitis, necrotizing fasciitis, and so on.”

Additionally:

“Physical examination showed blister and a surrounding round erythematous patch at the right popliteal fossa and right inguinal lymphadenopathy,” the authors wrote.

Lyme disease skin rash

The woman was diagnosed clinically with “early Lyme disease with bullous erythema migrans.”

“Given the season, geographic location, outdoor activity, and progression despite treatment for cellulitis and shingles, she was clinically diagnosed with early Lyme disease,” the authors report.

The woman was treated for Lyme disease with a 10-day course of doxycycline and her skin rash resolved.

Laboratory tests for Lyme disease were negative – a common occurrence with early Lyme disease.

“The atypical appearance of skin rash might confuse physicians with many differential diagnoses, such as spider bite, herpes zoster, bullous cellulitis, necrotizing fasciitis, and so on,” the authors point out.

Editor’s comments:  I have seen rashes described in this article in my Lyme disease patients. I am concerned when a patient is diagnosed with shingles, cellulitis or necrotizing vasculitis before Lyme disease is considered as a possible cause of an atypical skin rash.

If uncertain about the root cause of the rash, I will typically treat patients with a combination of medications including an antiviral agent and an antibiotic that is effective in treating cellulitis, a spider bite and Lyme disease.
References:
  1. Suzuki H, Carlson JR, Matsumoto E. 43-Year-Old Female With Fever and Bullous Skin Lesion. Clin Infect Dis. Dec 17 2020;71(10):2763-2764. doi:10.1093/cid/ciaa206

_____________________

**Comment**

Everyone knows that delayed treatment for Lyme/MSIDS is causing chronic/persistent symptoms, yet it continually appears doctors would rather diagnose patients with anything other than Lyme/MSIDS.  It’s almost like they want to run through a litany of other causes first, treat for those, and finally if nothing works throw up the white flat and admit it’s tick-borne illness.

For more:

Please remember that those getting the rash is highly variable and certainly not a sure thing.  If you get it, it is diagnostic for Lyme – no testing needed; however, if you don’t get it, you can still be infected:

Rashes-larger-blog-4

Category:

Lyme, research

Babesia in a MS Patient

https://danielcameronmd.com/babesia-microti-multiple-sclerosis-patient/  Go Here for Podcast

BABESIA MICROTI IN A MULTIPLE SCLEROSIS PATIENT

babesia microti in MS patient

Welcome to another Inside Lyme Podcast. I am your host Dr. Daniel Cameron. In this episode, I will be discussing the case of a 54-year-old male with a 12-year history of multiple sclerosis who was diagnosed with Babesia microti.

By 

Haberli and colleagues describe the case in the journal Multiple Sclerosis and Related Disorders.1

Babesia microti, a tick-borne pathogen that infects red blood cells, can cause severe disease in immunocompromised individuals. This patient was immunocompromised due to multiple sclerosis (MS) and the immunosuppressive drug he was receiving, ocrelizumab.

Disease Modifying Therapy

Ocrelizumab (sold under the brand name Ocrevus™ in the US) was approved in 2017 for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody, which targets mature B-cells that contribute to demyelination and damage to nerve cells.

Ocrelizumab is a disease modifying therapy (DMT) approved to treat both primary progressive MS and relapse-remitting MS. Ocrevus™ can cost just over $65,000 per year if not covered by insurance.

The patient was prescribed Ocrevus™. 

“The use of ocrelizumab has been associated with increased risk of infections involving upper respiratory, gastrointestinal, and urinary tracts, in addition to herpes simplex reactivation,” wrote the authors. 

“Data from one randomized clinical trial has shown a statistically significant increase in the incidence of malignancy among ocrelizumab users compared to placebo and interferon β1,” they added.

Rituximab, a medication with a similar mechanism of action, has been associated with rare infections in non-MS patients including severe or relapsing Babesia microti infections, the authors wrote.

MS patient fails treatment

This is the first published case of Babesia microti in a patient treated with Ocrevus™.

The 54-year-old man had been diagnosed with major depressive disorder, hypertension and had a 12-year history of relapse-remitting multiple sclerosis.

He was hospitalized with malaise, fever, fatigue for one week and episodes of syncope. He failed treatment with 4 different disease modifying drugs ─ glatiramer acetate, natalizumab, dimethyl fumarate, and fingolimod.

The man refused further therapy and was lost to follow-up.

6 years later, MS symptoms worsen

Six years later, the man’s MS symptoms worsened and he was prescribed Ocrevus™.

Four months later, he was hospitalized and treated for possible sepsis. He had unexplained thrombocytopenia (low blood platelet count).

Tests positive for Babesia microti

As part of his sepsis work-up, the patient was tested for tick-borne infections with PCR test results for Babesia microti returning positive.

The man was treated with 500mg daily azithromycin and 750mg twice daily atovaquone. 

“At week 8, his therapy was discontinued due to complete resolution of pancytopenia, negative B. microti PCR, and negative Giemsa-stained blood smear,” wrote the authors.

There have been other cases of Babesia microti patients treated with Ocrevus™.  

“There were five babesiosis cases associated with ocrelizumab reported between June 2018 and August 2020 on the FAERS database,” the authors wrote.²

“There were two females and two males with an age range of 45 to 51 years old, and one female 65 to 85 years old, all of whom had serious events without reported fatalities,” wrote the authors based on a review of the FDA Adverse Event Reporting System (FAERS) public dashboard.

The following questions are addressed in this podcast episode:  

  1. What is Babesia microti?
  2. How do you diagnose Babesia?
  3. Is testing accurate?
  4. How severe is Babesia?
  5. Are there asymptomatic cases of Babesia?
  6. Why do immunosuppressive drugs pose a risk to Babesia patients?
  7. What are the risk factors for symptomatic Babesia?
  8. What is a disease modifying agent?
  9. What is Ocrevus™?
  10. What was the treatment for Babesia?
  11. What is the significance of 8 weeks of treatment with Babesia?
    Thanks for listening to another Inside Lyme Podcast. You can read more about these cases in my show notes and on my website @DanielCameronMD.com. As always, it is your likes, comments, reviews, and shares that help spread the word about Lyme disease. Until next time on Inside Lyme.

Please remember that the advice given is general and not intended as specific advice to any particular patient. If you require specific advice, then please seek that advice from an experienced professional.

Inside Lyme Podcast Series

This Inside Lyme case series will be discussed on my Facebook page and made available on podcast and YouTube.  As always, it is your likes, comments, and shares that help spread the word about this series and our work. If you can, please leave a review on iTunes or wherever else you get your podcasts.

References:
  1. Haberli N, Coban H, Padam C, Montezuma-Rusca JM, Creed MA, Imitola J. Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab. Mult Scler Relat Disord. Feb 2021;48:102731. doi:10.1016/j.msard.2020.102731
  2. Ezequiel M, Teixeira AT, Brito MJ, Luis C. Pseudotumor cerebri as the presentation of Lyme disease in a non-endemic area. BMJ Case Rep. 2018;2018.

________________________

**Comment**

This case brings up a very important point: MS can be caused or exacerbated by tick-borne infections. Immune-suppressing drugs are contraindicated for people with TBI’s. The only caveat to that is if they are used in conjunction with antibiotics.

I can’t help but wonder how many other patients are out there with this exact same scenario.

For more:

Category:

Babesia, research, Treatment